SynAct Pharma signs first commercial deal for resomelagon in Brazil
Sweden's SynAct Pharma has agreed with Hipolabor to co-develop and commercialise resomelagon for dengue in Brazil, with profits and costs split 50/50.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swedish biotech SynAct Pharma (Nasdaq Stockholm: SYNACT) has signed a strategic co-development and commercialisation agreement with Brazilian drugmaker Hipolabor Farmacêutica for resomelagon in dengue treatment in Brazil, according to TradingView, which cited the company's press release. Hipolabor will contribute its regulatory, manufacturing, distribution and commercial capabilities in the country.
Under the terms, profits from sales and development costs are shared equally, 50/50. Additional sales milestone payments are linked to cumulative net sales of USD 200 million. SynAct keeps full control over resomelagon and the right to seek partners for other indications and territories.
The drug is being developed as a short outpatient treatment that eases key dengue symptoms and lowers the risk of severe disease. Results from Part 1 of the RESOVIR-2 study are expected in 2026, and topline results of the full study in the second quarter of 2027.
why it matters
For markets, this is mainly news for one small-cap biotech. The main drivers remain the RESOVIR-2 results and regulator feedback, while the commercial impact will depend on approval and future sales in Brazil.
tags
instruments
sources
- SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company — TradingView, 27 October 2026 at 13:55 UTC
- SynAct Pharma Signs First Commercial Partnership For Resomelagon — Reuters, 27 October 2026 at 13:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗